Special Populations: Elderly Patients

  • Diana Crivellari
  • Lucia Fratino
Part of the Cancer Treatment and Research book series (CTAR, volume 151)


Breast Cancer Aromatase Inhibitor Comprehensive Geriatric Assessment Elderly Cancer Patient ATAC Trial 


  1. 1.
    Socio-economic factors and health care system characteristics related to cancer survival in the elderly A population-based analysis in 16 European countries (ELDCARE project) Quaglia A, Vercelli M, Lillini R, Mugnoc E, Coebergh JW, Quinn M, Martinez-Garcia C, Capocaccia R, Micheli A on behalf of the ELDCARE Working Group Crit Rev Oncol Hematol. 2005;54:117–28.PubMedCrossRefGoogle Scholar
  2. 2.
    Yancik RM, Ries L. Cancer and age: Magnitude of the problem. In Balducci L, Lyman GH, Ershler WB, eds. ComprehensiveGeriatric Oncology, 2nd ed. London: Harwood Academic; 1998:95–103.Google Scholar
  3. 3.
    Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Crit Rev Oncol Hematol. 2001;39:219–26.PubMedCrossRefGoogle Scholar
  4. 4.
    Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Changed trends of cancer mortality in the elderly. Ann Oncol. 2001;12:1467–77.PubMedCrossRefGoogle Scholar
  5. 5.
    Stuck AE, Aronow HU, Steiner A, et al. A trial of annual inhome comprehensive geriatric assessment for elderly people living in the community. N Engl J Med. 1995;333:1184–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Satariano WA, Ragland DR. The effect of Comorbidity on 3 year survival of women with primary breast cancer. ANN Int Med. 1994;120(2):104–10.Google Scholar
  7. 7.
    Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10:20–30,73.PubMedCrossRefGoogle Scholar
  8. 8.
    Lawton MP, Brody E. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.PubMedCrossRefGoogle Scholar
  9. 9.
    Fratino L, Ferrario L, Redmond K, Audisio RA. Global Health care: The role of geriatrician, general practitioner and oncology nurse. Crit Rev Oncol Hematol. 1998;27:101–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Stuck AK, Siu AL, Wieland DG, Adams J, Rubenstein LZ. Comprehensive geriatric assessment. A meta-analysis of controlled trials. Lancet. 1993;342:1032–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Monfardini S, Ferrucci L, Fratino L, Del Lungo I, Serraino D, Zagonel V. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer. 1996;77:395–401.PubMedCrossRefGoogle Scholar
  12. 12.
    Folstein ME, Folstein SE, McHugh PR. A mini mental state: a practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res. 1975;12:189–98.PubMedCrossRefGoogle Scholar
  13. 13.
    Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, Parodi S, Dal Lago D, Gioia F, Monfardini F, Aapro MS, Serraino D, Zagonel V. Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients An Italian Group for Geriatric Oncology Study. J Clinl Oncol. 2002;20(Issue 2):494–502.CrossRefGoogle Scholar
  14. 14.
    Balducci L, Beghè C. The application of the principlesof geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol. 2000;35:147–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology. 2000;14(11A):221–7.PubMedGoogle Scholar
  16. 16.
    Overcash JA, Beckstead J, Extermann M, Cobb S. The abbreviated comprehensive geriatric assessment (aCGA): A retrospective analysis. Crit Rev Oncol Hematol. 2005;54:129–36.PubMedCrossRefGoogle Scholar
  17. 17.
    Hurria A, Lachs MS, Cohenc HJ, Mussd HB, Kornblith AB. Geriatric assessment for oncologist: rationale and future directions. Crit Rev Oncol Hematol. 2006;59:211–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Fried LP, Tangen C, Walston J, et al. Frailty on older adults: Evidence for a phenotype. J Gerontol Med Sci. 2001;56:M146–M156.CrossRefGoogle Scholar
  19. 19.
    Balducci L, Stanta G. Cancer in the frail patient: a coming epidemic. Hematol Oncol Clin North Am. 2000;14:235–50.PubMedCrossRefGoogle Scholar
  20. 20.
    Sweeney C, Schmitz KH, Lazovich D, Virgin BA, Wallace RB, Folsom AR. Functional limitation in elderly female cancer survivors. J Natl Cancer Inst. 2006;98:521–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–717.PubMedCrossRefGoogle Scholar
  22. 22.
    Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Canc Res Treat. 2002;74:199–211.CrossRefGoogle Scholar
  23. 23.
    Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92:550–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Daidone MG, Coradini D, Martelli G, et al. Primary breast cancer in elderly women: Biological profile and relation with clinical outcome. Crit Rev Oncol Hematol. 2003;45:313–25.PubMedCrossRefGoogle Scholar
  25. 25.
    Molino A, Giovannini M, Auriemma A, et al. Pathological, biological and clinical characteristics, and surgical management of elderly women with breast cancer. Crit Rev Oncol Hematol. 2006;59:226–33.PubMedCrossRefGoogle Scholar
  26. 26.
    Audisio RA, Bozzetti F, Gennari R, et al. The surgical management of elderly cancer patients: recommendations of the SIOG surgical task force. Eur J Cancer. 2004;40:926–38.PubMedCrossRefGoogle Scholar
  27. 27.
    Ramesh HS, Jain S, Audisio RA. Implications of age in surgical oncology. Cancer. 2005;11(6):488–94.CrossRefGoogle Scholar
  28. 28.
    Gazet JC, Ford H, Coombes RC. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Eur J Surg Oncol. 1994;20:207–14.PubMedGoogle Scholar
  29. 29.
    Robertson JFR, Todd JH, Ellis IO, et al. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJd. 1998;297:917–8.Google Scholar
  30. 30.
    Mustacchi G, Ceccherini R, Dilani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: Long term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol. 2003;14:414–20.PubMedCrossRefGoogle Scholar
  31. 31.
    Bates T, Riley DL, Houghton J, et al. Breast cancer in elderly women: A Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg. 1991;78:591–4..PubMedCrossRefGoogle Scholar
  32. 32.
    Verkooijen HM, Fioretta GM, Rapiti E, et al. Patient’s refusal of surgery strongly impairs breast cancer survival. Ann Surg. 2005;242:276–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane or tamoxifen in postmenopausal patients – A randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol. 2004;23:6(abs 515).Google Scholar
  35. 35.
    Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18:3758–67.PubMedGoogle Scholar
  36. 36.
    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12:1527–32.PubMedCrossRefGoogle Scholar
  37. 37.
    Mouridsen H, Chaudri-Ross HA. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. Oncologist. 2004;9:497–506.PubMedCrossRefGoogle Scholar
  38. 38.
    Veronesi U, Boyle P, Goldhirsch A, et al. Breast Cancer. Lancet. 2005;365:1727–41.PubMedCrossRefGoogle Scholar
  39. 39.
    International Breast Cancer Study Group. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: First results of International Breast Cancer Study Group Trial 10–93. J Clin Oncol. 2006;24:337–44.CrossRefGoogle Scholar
  40. 40.
    Vinh-Hung V, Verschraegen C. Breast conserving surgery with or without radiotherapy: Pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004;96:115–21.PubMedCrossRefGoogle Scholar
  41. 41.
    Fyles A, McCready D, Manchul L, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351:1021–3.CrossRefGoogle Scholar
  42. 42.
    Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: A report of further follow-up. SABCS (abs December 2006).Google Scholar
  44. 44.
    Prescott RJ, Hunkler IH, Williams LJ, et al. PRIME I: Assessing the impact of adjuvant breast radiotherapy on quality of life in low risk older patients following breast conservation. Breast. 2007;(16):S35.Google Scholar
  45. 45.
    Veronesi U, Orecchia R, Luini A. A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer. 2001;37:2178–83.PubMedCrossRefGoogle Scholar
  46. 46.
    Vaidya JS, Baum M, Tobias JS, et al. Targeted Intraoperative Radiotherapy (TARGIT)-trial protocol. Lancet online (1999). Available at: http://www.thelancet.com/journals/lancet/misc/protocol/99PRT-47.
  47. 47.
    Orecchia R, Ciocca M, Lazzari R. Intraoperative radiation therapy with electrons (ELIOT) in early stage breast cancer. Breast. 2003;12:483–90.PubMedCrossRefGoogle Scholar
  48. 48.
    Eifel P, Axelson JA, Costa J, et al. National Institute of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1–3 (2000). J Natl Cancer Inst. 2001;93:979–89.PubMedCrossRefGoogle Scholar
  49. 49.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–717.PubMedCrossRefGoogle Scholar
  50. 50.
    Crivellari D, Price K, Gelber RD, et al. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer. 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol. 2003;21:4517–23.PubMedCrossRefGoogle Scholar
  51. 51.
    Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569–83.PubMedCrossRefGoogle Scholar
  52. 52.
    ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet. 2002;359:2131–9.CrossRefGoogle Scholar
  53. 53.
    ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.CrossRefGoogle Scholar
  54. 54.
    Coleman RE on behalf of the ATAC Trialists’ Group. Effect of anastrozole on bone mineral density: 5-year results from the “Arimidex, tamoxifen, Alone or in combination (ATAC) trial. Proc Am Soc Clin Oncol. 2006 (abs 511).Google Scholar
  55. 55.
    Coates A, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1–98. J Clin Oncol. 2007;25:486–92.Google Scholar
  56. 56.
    Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the use of Aromatase Inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor-positive breast cancer: Status Report 2004. J Clin Oncol. 2005;3:1–11.Google Scholar
  57. 57.
    Coombes RC, Hall E, Gibson LJ, et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–92.PubMedCrossRefGoogle Scholar
  58. 58.
    Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole (ITA) trial. J Clin Oncol. 2005;23:5138–47.PubMedCrossRefGoogle Scholar
  59. 59.
    Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–62.PubMedCrossRefGoogle Scholar
  60. 60.
    Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early breast cancer. N Engl J Med. 2003;349:1793–802.PubMedCrossRefGoogle Scholar
  61. 61.
    Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG 6a). Proc Am Soc Clin Oncol. 2005;23(abs 105).Google Scholar
  62. 62.
    Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet. 1998;352:930–42.CrossRefGoogle Scholar
  63. 63.
    Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293:1073–81.PubMedCrossRefGoogle Scholar
  64. 64.
    Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: Assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24:2757–64.PubMedCrossRefGoogle Scholar
  65. 65.
    Giordano SH, Duan Z, Kuo F-Y, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Pritchard KI, Paterson AH, Fine S, et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol. 1997;15:2302–11.Google Scholar
  67. 67.
    Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000;18:1412–22.PubMedGoogle Scholar
  68. 68.
    Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990;8:1005–18.PubMedGoogle Scholar
  69. 69.
    Wils JA, Bliss JM, Marty M, et al. Epirubicin plus tamoxifen vs tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol. 1999;17:1988–98.PubMedGoogle Scholar
  70. 70.
    Fargeot P, Bonneterre J, Rochè H, et al. Disease-free survival advantage of weekly Epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French Adjuvant Study Group 08 trial. J Clin Oncol. 2004;23:4622–30.Google Scholar
  71. 71.
    Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 2003;97:2869–79.PubMedCrossRefGoogle Scholar
  72. 72.
    Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol. 2003;51:395–402.PubMedGoogle Scholar
  73. 73.
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRefGoogle Scholar
  74. 74.
    Winer EP, Carey LA, Dowsett M, et al. Beyond anatomic staging: Are we ready to take the leap to molecular classification? ASCO Proc. 2005;46–59.Google Scholar
  75. 75.
    Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen treated, node negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Diana Crivellari
    • 1
  • Lucia Fratino
    • 2
  1. 1.Division of Medical Oncology CCentro di Riferimento Oncologico National Cancer InstituteAvianoItaly
  2. 2.Division of Medical Oncology ANational Cancer InstituteAvianoItaly

Personalised recommendations